Answers are grounded in this paper and cite their sources.
Vaccines using protein antigens are utilized as an important modality due to their proven track record and high safety profile. However, protein antigens present challenges, such as low cell membrane permeability and easy degradation in cells. In addition, to induce an efficient immune response, the antigen must be delivered to antigen-presenting cells (APCs). Therefore, the development of a carrier that can overcome these challenges is required. We previously developed an aminated polyrotaxane that recognizes and adapts to the shapes and charge distributions of biopharmaceuticals to form complexes efficiently. We also developed a second-generation aminated polyrotaxane (2G) with excellent endosome escape ability. In this study, to deliver antigens to APCs, we modified 2G with mannose, a ligand that recognizes APCs (Man-Phe-2G). Man-Phe-2G formed a complex with the model antigen ovalbumin (OVA) and significantly enhanced its internalization in mouse bone marrow-derived dendritic cells (BMDC) compared to the 2G/OVA complex. In addition, Man-Phe-2G/OVA significantly increased the expression of antigen-presenting markers and co-stimulatory molecules in BMDC, the production of IL-12 from BMDC, and the production of anti-OVA IgG in vivo , compared to OVA alone or 2G/OVA complex. These results suggest that Man-Phe-2G is a useful antigen delivery carrier for APCs.
No takes yet. Share an insight, caveat, or question.
Katanosaka et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: